Science & Portfolio

Science & Product

Licensed access to a portfolio of clinical-stage compounds spanning multiple therapeutic areas: Dermatology, Ophthalmology, Oncology, Neurology.

Opportunity

Portfolio Acquisition Opportunity

At the forefront of medical innovation — both novel drugs and repurposed innovation (DRPx).

⅓
the cost
vs. traditional development
⅓
the time to market
faster to patients
80%
lower risk
de-risked pathway
Delivered by a top team: Research Patent Wet Lab
600+
Portfolio of over
International Patents Published
500+ Patent Applications
50+ US Granted Patents
30+ US Published Patents
20+ Pipeline Molecules
6 Lead Candidates for Clinical Development
Business Model

Orchestrated Development Approach

End-to-end orchestration with success-based alignment.

IP Acquire
  • Inventor roll-over
Strategic Domicile
  • Trust / brand value
  • Investment incentive
  • Ecosystem cluster
Therapeutic Cluster
  • Optimize cost & risk — participation opportunity for CRO, KOL, market research
Establish SPV & Governance
  • Traditional entity or DAO (DESCI)
  • Milestone plan
  • Assign equity for milestone-based earn-in
Leadership Appointment
  • Cash-minimal model with success-based equity earn-in

Result = an investible structure positioned for clinical milestones

Investible Vehicle

  • ✓ Investor aligned
  • ✓ Derisked
  • ✓ Execution ready
Motivated Leadership · CEO & CSO
Governed Entity
Intellectual Property

Focus on Success

  • ✓ Optimized clinical pathway
  • ✓ Clinical milestones
  • ✓ P2/3 exit
Subsidiary

OrchestratePharma establishes SPV (subsidiary) in Sweden

Celfex AB has sub-licensed from OrchestratePharma the right to develop fexofenadine. A topical formulation of fexofenadine shall target mild to medium atopic dermatitis. Celfex AB shall enter a Phase 2 clinical study together with several co-development CRO partners in Asia and Europe.

Fexofenadine (Celfex) Key Mechanisms

H1R Blocking

Potent H1 receptor antagonism reduces histamine-mediated itch and inflammation.

Anti-inflammatory

Demonstrated anti-inflammatory properties beyond antihistamine effects, reducing cytokine production.

Dysbiosis Correction

Potential to restore healthy skin microbiome balance disrupted in eczema and other skin conditions.

Moisture Retention

Supports skin barrier function and helps maintain proper hydration levels.

Barrier Repair

Promotes restoration of the skin's natural protective barrier compromised in dermatological conditions.

Antimicrobial

Exhibits antimicrobial properties that may help prevent secondary infections in damaged skin.

Learn More About our IP Portfolio & Investment Models

Explore our portfolio of IP and discuss investment or co-development opportunities.

Contact Us